Higher Risk Myelodysplastic Syndrome clinical trials

Explore recruiting higher risk myelodysplastic syndrome clinical trials.

Recruiting higher risk myelodysplastic syndrome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Higher Risk Myelodysplastic Syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)

Czechia, Belgium, Austria, Spain, Netherlands, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Global Multicenter, Double-Blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4)

Poland, Italy, Greece, Czechia, Bulgaria, Hungary +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) (ASPEN-02)

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

Denmark, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome

Austria, Poland, Czechia, Belgium, Germany, Spain +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2A, Open Label Dose Escalation and Cohort Expansion Study of Orally Administered CA-4948 (IRAK4i) as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Germany, Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Higher Risk Myelodysplastic Syndrome trials by city

Higher Risk Myelodysplastic Syndrome in Toronto Higher Risk Myelodysplastic Syndrome in Vancouver Higher Risk Myelodysplastic Syndrome in Montreal Higher Risk Myelodysplastic Syndrome in Calgary Higher Risk Myelodysplastic Syndrome in Edmonton Higher Risk Myelodysplastic Syndrome in Ottawa Higher Risk Myelodysplastic Syndrome in Winnipeg Higher Risk Myelodysplastic Syndrome in Quebec City Higher Risk Myelodysplastic Syndrome in Hamilton Higher Risk Myelodysplastic Syndrome in Kitchener Higher Risk Myelodysplastic Syndrome in London Higher Risk Myelodysplastic Syndrome in Halifax Higher Risk Myelodysplastic Syndrome in New York Higher Risk Myelodysplastic Syndrome in Los Angeles Higher Risk Myelodysplastic Syndrome in Chicago Higher Risk Myelodysplastic Syndrome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease